

INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI 2024

**C. Patrick Reynolds,
M.D., PhD.,
Cancer Center Director for the School
of Medicine, Texas Tech University Health
Sciences Center, Lubbock, USA, Director
of the South Plains Oncology Consortium,
and the ALSF/COG Childhood Cancer Repository**



Dr. Reynolds grew up in El Paso, TX, received his BA in Biology from The University of Texas at Austin, his MD from UT Southwestern Medical School in Dallas, TX, his PhD (Cell Biology) from UT Austin, and his pediatrics training at the National Naval Medical Center. His postdoctoral fellowship was in cancer immunology at UT Southwestern Medical School, Dallas, TX. He holds the rank of Commander, US Navy (retired). He is currently the Cancer Center Director for the School of Medicine, Texas Tech University Health Sciences Center (<http://cancer.ttuhscc.edu>), and is Director of the South Plains Oncology Consortium (SPOC: www.SPONC.org) and the ALSF/COG Childhood Cancer Repository (www.CCcells.org).

Dr Reynolds' research focuses cancer developmental therapeutics and he pioneered the development of the differentiating agent isotretinoin for treating the childhood cancer neuroblastoma. His most recent research focuses on two areas: 1) Use of telomere maintenance mechanisms as cancer biomarkers for neuroblastoma and other cancers and developing agents to specifically target alternate telomere lengthening (ALT) cancers. 2) Assessing GD2 expression on neuroblastoma cells as a mechanism of resistance to chemoimmunotherapy and developing novel non-GD2 anti-neuroblastoma antibodies. Other research interests include mechanisms of resistance to drugs and antibody therapy in childhood and adult cancers, biobanking of human cancers, and development of novel preclinical testing systems for cancer drug development.

Dr. Reynolds is a member of the neuroblastoma steering committee for the Children's Oncology Group (COG). He was a special government employee with the FDA for 20 years and a founding member of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee for the FDA. He is a founding member of the Advisory Committee on Childhood Cancer and the Clinical Trials Committee and the Clinical Trials Advisory Committee for the Cancer Prevention and Research Institute of Texas (CPRIT). He has served on multiple NIH study sections. He is a member of the BPCA Pediatric Oncology Working Group for the National Institute for Child Health and Development. Honors received include the 2004 Eurand Prize, 2008 Advances in Neuroblastoma Research Best Clinical Paper, the most cited paper in Clinical Cancer Research in 2009, The Texas Tech Chancellor's research award, the Covenant Health Systems David R. Close, MD Endowed Chair in Oncology, and TTUHSC Distinguished University Professor.

Dr. Reynolds has sponsored multiple investigational New Drug (IND) applications with the FDA and receives grant funding from the NIH, DOD, and CPRIT. Dr. Reynolds is an author or co-author of over 250 peer-reviewed scientific papers with > 30,000 citations (H Index = 86) and he is a co-inventor on multiple issued and pending patents. He serves on the editorial boards of *Clinical Cancer Research* and *Molecular Cancer Therapeutics*. His avocations include film making and special effects, playing guitar, and writing music. He also enjoys competitive shooting and he was the team physician for the 1992 USA Olympic shooting team in Barcelona.